Global News

CenterWatch launches new version of Clinical Trials Listing Service

Friday, September 6, 2013 02:51 PM

CenterWatch, a publisher of clinical trials information for patients and professionals, has launched a revamped version of its award-winning Clinical Trials Listing Service (CTLS) to better serve the public and patient communities. 

More... »

Ximedica, Theorem collaborate

Friday, September 6, 2013 02:44 PM

Global CRO Theorem Clinical Research is collaborating with Ximedica, a medical product development firm.

More... »

Accelrys acquires ChemSW

Wednesday, September 4, 2013 03:59 PM

Accelrys, a provider of scientific innovation lifecycle management software, has acquired ChemSW, an Environmental Health & Safety (EH&S) compliance solutions provider. This acquisition furthers Accelrys' scientific innovation lifecycle management strategy by providing solutions for managing and tracking the source, use and disposal of chemicals along the entire lab-to-plant value chain.

More... »

Heidelberg Pharma, Roche ink license agreement

Wednesday, September 4, 2013 03:57 PM

Germany-based Heidelberg Pharma, a wholly owned subsidiary of Wilex, has signed a license agreement with Roche covering the development of a novel class of antibody drug conjugates (ADCs) based on Heidelberg Pharma’s patented technology to couple α-Amanitin to antibodies. The license agreement covers initial joint research to apply this technology to multiple Roche antibodies towards the identification of development candidates with favorable efficacy/safety profiles.

More... »

Mylan receives approval from India, acquires Agila

Wednesday, September 4, 2013 03:53 PM

Global pharmaceutical company Mylan’s proposed acquisition of the Agila injectables businesses from Indian pharmaceutical company Strides Arcolab has received approval from India's Foreign Investment Promotion Board (FIPB). The transaction also received approval from the Cabinet Committee on Economic Affairs (CCEA). The transaction is expected to close in the fourth quarter of 2013.

More... »

bioMérieux acquires BioFire Diagnostics

Wednesday, September 4, 2013 03:51 PM

bioMérieux, an in vitro diagnostics company, has acquired BioFire Diagnostics, a privately-held U.S.-based company specialized in molecular biology. BioFire invented, manufactures and commercializes its multiplex PCR FilmArray system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases.

More... »

iPierian to launch True North Therapeutics

Wednesday, September 4, 2013 03:48 PM

iPierian, a biotechnology company developing novel therapies for neurodegenerative disease, has secured financing of $30 million  to continue to advance its drug development in neurodegenerative disease and  to launch a spin-out company, True North Therapeutics.

More... »

Elcelyx Therapeutics spins out NaZura BioHealth

Wednesday, September 4, 2013 03:47 PM

Elcelyx Therapeutics has established NaZura BioHealth, a separate company focusing on development of Gut Sensory Modulators (GSM) including lead product Lovidia, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet, the company’s proprietary delayed-release formulation of metformin for the treatment of patients with type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

More... »

Brisk pace of drug outsourcing deals continues in first half of 2013

Wednesday, September 4, 2013 12:26 PM

Crosstree Capital Partners, an investment banking company specializing in advising middle market companies in the drug and device outsourcing industry, has released its second quarter 2013 Drug and Device Outsourcing Industry Monitor.

More... »

VelaLabs, Evercyte collaborate for biosimilar characterization

Wednesday, September 4, 2013 12:25 PM

VelaLabs, a provider of analytical services to the global biopharmaceutical industry, and Evercyte, a producer of standardized, relevant cell systems, are cooperating to commercialize immortalized target cells for the characterization of biosimilars in a GMP environment.

More... »